 Patients receive yttrium Y 90 glass microspheres intraarterially IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, nivolumab will be administered intravenously IV over approximately 60 minutes every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent. 